Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Vaccine

• Publication date

  2010-08-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2010.06.065PMID 20600478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

  2010cited by this paper
• Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years: A Phase II, Randomized, Open, Controlled Study

  2010cited by this paper
• Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

  2010cited by this paper
• Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.

  2010cited by this paper
• Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

  2010cited by this paper
• Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome.

  2009cited by this paper
• Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United States

  2009cited by this paper
• Critically Ill patients with 2009 influenza A(H1N1) in Mexico.

  2009cited by this paper
• Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.

  2009cited by this paper
• Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

  2009cited by this paper
• Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

  2009cited by this paper
• Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

  2009cited by this paper
• Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

  2009cited by this paper
• Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings

  2009cited by this paper
• A novel influenza A (H1N1) vaccine in various age groups.

  2009cited by this paper
• Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study

  2009cited by this paper
• Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

  2009cited by this paper
• Critically ill patients with 2009 influenza A(H1N1) infection in Canada.

  2009cited by this paper
• Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis.

  2009cited by this paper
• Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

  2009cited by this paper
• MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

  2009cited by this paper
• Response to a monovalent 2009 influenza A (H1N1) vaccine.

  2009cited by this paper
• H1N1 pandemic flu found to cause viral pneumonia in severe cases, says WHO

  2009cited by this paper
• Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

  2009cited by this paper
• Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

  2009cited by this paper
• An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

  2008cited by this paper
• Children, avian influenza H5N1 and preparing for the next pandemic

  2008cited by this paper
• Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

  2008cited by this paper
• Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans.

  2008cited by this paper
• Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

  2007cited by this paper
• Pre- or post-pandemic influenza vaccine?

  2007cited by this paper
• Incidence, Complications, and Risk Factors for Prolonged Stay in Children Hospitalized With Community-Acquired Influenza

  2007cited by this paper
• Influenza-Related Hospitalizations in Children Younger Than Three Years of Age

  2006cited by this paper
• Mitigation strategies for pandemic influenza in the United States.

  2006cited by this paper
• Strategies for mitigating an influenza pandemic

  2006cited by this paper
• HOSPITAL-BASED EPIDEMIOLOGIC SURVEY OF MALIGNANCIES IN CHILDREN INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS IN THAILAND

  2005cited by this paper
• A Comparison of 2 Influenza Vaccine Schedules in 6- to 23-Month-Old Children

  2005cited by this paper
• Influenza-associated deaths among children in the United States, 2003-2004.

  2005cited by this paper
• Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix™

  2002cited by this paper
• Safety and immunogenicity of a paediatric presentation of an influenza vaccine

  2000cited by this paper
• Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays

  1999cited by this paper

• Downregulation of hypocretin/orexin after H1N1 Pandemrix vaccination of adolescent mice.

  2024cites this paper
• Adjuvant potential of Peyssonnelia caulifera extract on the efficacy of an influenza vaccine in a murine model

  2024cites this paper
• A Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated with a Recombinant Cytomegalovirus (CMV) Pentamer Antigen in Mice

  2023cites this paper
• Narcolepsy Type I as an autoimmune disorder.

  2021cites this paper
• Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.

  2019cites this paper
• The Importance of Vaccinating Children and Pregnant Women against Influenza Virus Infection

  2019cites this paper
• Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine.

  2019cites this paper
• Establishment of a novel safety assessment method for vaccine adjuvant development.

  2018cites this paper
• 31 – Inactivated Influenza Vaccines

  2018cites this paper
• Prostaglandin D2 Receptor DP1 Antibodies Predict Vaccine-induced and Spontaneous Narcolepsy Type 1: Large-scale Study of Antibody Profiling

  2018cites this paper
• Adjuvanted influenza vaccines

  2018cites this paper
• Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.

  2017cites this paper
• Vaccine approaches conferring cross-protection against influenza viruses

  2017cites this paper
• AS03- and MF59-Adjuvanted Influenza Vaccines in Children

  2017cites this paper
• From discovery to licensure, the Adjuvant System story

  2016cites this paper
• Childhood and adolescent influenza vaccination in Europe: A review of current policies and recommendations for the future

  2016cites this paper
• Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age

  2016cites this paper
• Protection of young children from influenza through universal vaccination

  2015cites this paper
• Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials

  2015cites this paper
• Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

  2015cites this paper
• Caracterização fenotípica e funcional da resposta imune de voluntários imunizados contra influenza A (H1N1)pdm09

  2015cites this paper
• The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper.

  2015cites this paper
• An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.

  2014cites this paper
• [Immunological adjuvants. Determinant factors in the efficacy-toxicity ratio of the contemporary vaccines].

  2014cites this paper
• Vaccine adjuvants--understanding molecular mechanisms to improve vaccines.

  2014cites this paper
• Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial

  2014cites this paper
• Antibodies to Influenza Virus A/H1N1 Hemagglutinin in Type 1 Diabetes Children Diagnosed Before, During and After the SWEDISH A(H1N1)pdm09 Vaccination Campaign 2009–2010

  2014cites this paper
• A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months

  2014cites this paper
• Adyuvantes inmunológicos. Determinantes en el balance eficacia-toxicidad de las vacunas contemporáneas

  2014cites this paper
• Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine

  2013cites this paper
• Increased transmissibility explains the third wave of infection by the 2009 H1N1 pandemic virus in England

  2013cites this paper
• Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study

  2013cites this paper
• Evaluation of Biocompatibility and Administration Site Reactogenicity of Polyanhydride‐Particle‐Based Platform for Vaccine Delivery

  2013cites this paper
• Adjuvanted versus nonadjuvanted influenza vaccines in young children: comparing results from recent clinical trials

  2013cites this paper
• Effectiveness of Nonadjuvanted Monovalent Influenza A(H1N1)pdm09 Vaccines for Preventing Reverse Transcription Polymerase Chain Reaction–Confirmed Pandemic Influenza Hospitalizations: Case-Control Study of Children and Adults at 10 US Influenza Surveillance Network Sites

  2013cites this paper
• Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.

  2013cites this paper
• 17 – Inactivated influenza vaccines

  2013cites this paper
• Synthetic nanoparticle-based vaccines against respiratory pathogens

  2013cites this paper
• Polyanhydride particle platform for design of novel influenza vaccines

  2013cites this paper
• Nanoparticles, immunomodulation and vaccine delivery

  2013cites this paper
• An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants

  2013cites this paper
• Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

  2012cites this paper
• Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children

  2012cites this paper
• The Safety of H1N1 Vaccine in Children in Saudi Arabia

  2012cites this paper
• Successful H1N1 Influenza Vaccination of Children Receiving Chemotherapy for Solid Tumors

  2012cites this paper
• Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

  2012cites this paper
• Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine

  2012cites this paper
• A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory.

  2012cites this paper
• Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

  2012cites this paper
• Randomized, Multicenter Trial of a Single Dose of AS03-adjuvanted or Unadjuvanted H1N1 2009 Pandemic Influenza Vaccine in Children 6 Months to <9 Years of Age: Safety and Immunogenicity

  2012cites this paper
• Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza.

  2012cites this paper
• Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.

  2012cites this paper
• Development of a novel adjuvant platform for neonatal vaccines against pertussis

  2012cites this paper
• 2012 Landes Bioscience. Do not distribute. Influenza vaccination for older adults

  2012cites this paper
• AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

  2012cites this paper
• Preventing influenza in younger children.

  2012cites this paper
• Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil.

  2012cites this paper
• Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults

  2012cites this paper
• Adjuvanted influenza vaccines

  2012cites this paper
• Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.

  2012cites this paper
• Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain.

  2011cites this paper
• Selection of Adjuvants for Enhanced Vaccine Potency

  2011cites this paper
• [Current events in vaccination].

  2011cites this paper
• Panvax®: a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009

  2011cites this paper
• Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients.

  2011cites this paper
• Different influenza vaccine formulations and adjuvants for childhood influenza vaccination.

  2011cites this paper
• Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines

  2011cites this paper
• Safety of pandemic H1N1 vaccines in children and adolescents.

  2011cites this paper
• Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta‐analysis

  2011cites this paper
• A Rapid Flp-In System for Expression of Secreted H5N1 Influenza Hemagglutinin Vaccine Immunogen in Mammalian Cells

  2011cites this paper
• Influenza virus vaccines: lessons from the 2009 H1N1 pandemic.

  2011cites this paper
• Post-Pandemic Seroprevalence of Pandemic Influenza A (H1N1) 2009 Infection (Swine Flu) among Children <18 Years in Germany

  2011cites this paper
• Effectiveness of Pandemic H1N1 Vaccine Against Influenza-Related Hospitalization in Children

  2011cites this paper
• Present and future of influenza prevention in pediatrics

  2011cites this paper
• Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities

  2011cites this paper
• MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

  2011cites this paper
• Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance.

  2011cites this paper
• An Overview on the Field of Micro- and Nanotechnologies for Synthetic Peptide-Based Vaccines

  2011cites this paper
• Actualités en matière de vaccination

  2011cites this paper
• afety of pandemic H 1 N 1 vaccines in children and adolescents

  2011cites this paper
• [Current events in vaccination].

  2011cites this paper
• Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.

  2011cites this paper
• Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients.

  2011cites this paper
• Effectiveness and safety of influenza vaccination in children: European perspective.

  2011cites this paper
• Strategies for successful rapid trials of influenza vaccine

  2011cites this paper
• Atypical Gianotti-Crosti syndrome following administration of the AS03-adjuvanted H1N1 vaccine.

  2011cites this paper
• Two doses of pandemic influenza A(H1N1) vaccine: Tolerability in healthy young children in the Netherlands

  2011cites this paper
• Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children

  2011cites this paper
• Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden.

  2011cites this paper
• Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.

  2011cites this paper
• Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children.

  2011cites this paper
• Inactivated Influenza Vaccines

  2011cites this paper
• Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.

  2011cites this paper
• Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

  2010cites this paper